March 31, 2009
FDA close to approval of brain cancer drug
A U.S. Food and Drug Administration committee is recommending accelerated approval of the drug Avastin for treating brain cancer.
Drug maker Genentech Inc. said the FDA is expected to make a decision next month on use of the colon cancer drug in patients with previously treated glioblastoma, the most aggressive form of brain cancer.
Dr. David Schenkein of Genentech said a Phase III trial evaluating Avastin in people with newly diagnosed glioblastoma will be initiated later this year.